← Back

SSY Group Ltd

SSY Group Limited, an investment holding company, researches, develops, manufactures, trades, and sells various pharmaceutical products to hospitals and distributors in the People's Republic of China and internationally. The company offers intravenous infusion solutions, including non-PVC and upright soft bag, PP plastic bottle, and glass bottle infusion solutions, as well as ampoule injections. It also provides small volume injections, oral preparations, chinese medicine preparations, and biological preparations, as well as bulk pharmaceutical products and medical materials. In addition, the company is involved in the research, development, and consulting of pharmaceutical technology; provision of logistics services for pharmaceutical products; food, beverages, and catering businesses; research, development of biotechnology and related roducts; and production and sale of methylamine. It sells its products under the Shimen brand name. The company was formerly known as Lijun International Pharmaceutical (Holding) Co., Ltd. and changed its name to SSY Group Limited in May 2015. SSY Group Limited was founded in 1999 and is headquartered in Wan Chai, Hong Kong.

Price · split & dividend adjusted
News & notes moving 2005.HK
2005.HK

哈三聯、2026年上半期に3800万~4800万元の赤字見込み

哈三聯が業績予想を開示し、2026年上半期の親会社株主に帰属する純損失が3800万元から4800万元となる見通しを明らかにした。前年同期は9239万400元の赤字だった。同期の営業収入は4億2900万元、非経常損益を除いた純損失は4700万元から5700万元、基本1株当たり損失は0.12元から0.15元となる見込み。発表によると、国家医薬品集中購買政策や一部の非集中購買製剤市場での競争激化により製品価格が低迷し、固定費の負担が重く粗利で期間費用を賄えないことが赤字の直接的な原因だ。さらに、同社が投資する香港上場の石四薬集団の公正価値が引き続き下落し、報告期間中の公正価値変動損失は979万200元となった。
中国证券报·44d続きを読む ▾